Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 2,269-2,280 of 10,592
Drug study icon
CompletedNCT01861847

7-Keto DHEA for PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In United States
PTSDDrugA study involving a medication or substance.From 18 Years to 64 Years
Countries
United States
Sponsor
Humanetics Corporation
Condition
PTSD
Behavioral study icon
CompletedNCT05486312

7-week Study With CT-155 in People With Schizophrenia

This study exists to see whether the medication CT-155 can play a useful role in care. Researchers are trying to understand whether the medication CT-155 can make support easier to access outside standard clinic visits.

Remote / online
SchizophreniaBehavioralFrom 18 Years to 64 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT04235686

8 Week Multi-site Study of MYDAYIS® for Depression in bipolarity

This study exists to see whether the medication MYDAYIS can play a useful role in care. Researchers are trying to understand how people respond to the medication MYDAYIS in practice and what may need to be adjusted.

In United States
Bipolarity, DepressionDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Mayo Clinic
Condition
Bipolarity, Depression
Drug study icon
CompletedNCT01714713

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

In United States
SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States, Australia, Canada, ...
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Drug study icon
CompletedNCT02059642

MG01CI 1400 mg Compared With Placebo for ADHD

This study is completed in the United States and in Israel. It is testing MG01CI 1400 mg Compared With Placebo for ADHD.

In United States
ADHDDrugFrom 18 Years to 55 Years
Countries
United States, Israel
Sponsor
Alcobra Ltd.
Condition
ADHD
Drug study icon
CompletedNCT05024747

21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) for Addiction

This study is completed in the United States. It is testing 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) for Addiction.

In United States
AddictionDrugFrom 21 Years to 55 Years
Countries
United States
Sponsor
HALEON
Condition
Addiction
Drug study icon
CompletedNCT05113771

Liafensine for Depression

This study is completed in the United States and in Canada. It is testing liafensine for Depression.

In United States
DepressionDrugFrom 18 Years to 70 Years
Countries
United States, Canada
Sponsor
Denovo Biopharma LLC
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.